Gerard M.P. Giblin

Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial

Joanna M. Zakrzewska, Joanne Palmer, Valérie Morisset et al. · The Lancet Neurology · 2017 · 196 citations · Full text

Medicine, Neurology, Pharmacotherapy +7

Discovery of 2-[(2,4-Dichlorophenyl)amino]- <i>N</i> -[(tetrahydro- 2 <i>H</i> -pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a Selective CB2 Receptor Agonist for the Treatment of Inflammatory Pain

Gerard M.P. Giblin, Celestine T. O’Shaughnessy, Alan Naylor et al. · Journal of Medicinal Chemistry · 2007 · 120 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

GW627368X ((<i>N</i>‐{2‐[4‐(4,9‐diethoxy‐1‐oxo‐1,3‐dihydro‐2<i>H</i>‐benzo[<i>f</i>]isoindol‐2‐yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP₄ receptor antagonist

Richard J. Wilson, Gerard M.P. Giblin, Susan Roomans et al. · British Journal of Pharmacology · 2006 · 79 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +10

Non-acidic pyrazole EP1 receptor antagonists with in vivo analgesic efficacy

Adrian Hall, Andy Billinton, Susan H. Brown et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 76 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Discovery of 1-[4-(3-Chlorophenylamino)-1-methyl-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a Brain Penetrant 5-Azaindole CB₂Agonist for the Treatment of Chronic Pain

Gerard M.P. Giblin, Andrew Billinton, Michael A. Briggs et al. · Journal of Medicinal Chemistry · 2009 · 55 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15